Early Data Demonstrate Anti-TSLP Therapy Reduces Early and Late Asthmatic Responses and Several Key Inflammatory Markers
Amgen has announced that The New England Journal of Medicine (NEJM) published positive results from a Phase I study adding to the growing body of evidence that inhibiting thymic stromal lymphopoietin (TSLP) could be beneficial in the treatment of asthma. TSLP is a cytokine thought to be a key driver of allergic inflammation. These are the first clinical data to be reported for an anti-TSLP therapy. The results were also presented at the American Thoracic Society 2014 international conference taking place in San Diego.
Results from the 31-patient study showed treatment for 12 weeks with AMG 157, a monoclonal antibody that inhibits the activity of TSLP, resulted in statistically significant reductions in early asthmatic responses (EAR) and late asthmatic responses (LAR) in the airways following allergen challenges in patients with allergic (atopic) asthma. The data also showed statistically significant decreases in baseline markers of inflammation in the airways. Overall, adverse events were similar across treatment and placebo groups (15 events in the treatment arm versus 12 events in the placebo arm), with no serious adverse events occurring in the study.
"While these data are very early, they help to confirm our belief that TSLP is a critical early mediator that may be responsible for persisting airway inflammation and triggering the inflammatory response to allergens in allergic asthmatic patients," said Paul M. O'Byrne, MB, FRCPC, FRSC, executive director of the Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada. "These results form the basis for further development of this compound."
AMG 157 is a monoclonal immunoglobulin IgG2? that binds to and inhibits TSLP from interacting with its receptor. TSLP is a cytokine that is believed to play a critical role in the start of the allergic cascade, specifically the inflammatory response, and is generated by lung tissue when an allergen is introduced. Studies have also shown higher amounts of TSLP were produced in the lung tissue of individuals with asthma compared to healthy individuals, and the TSLP gene has been associated with both childhood and adult allergic asthma.
"Understanding the underlying biology of disease is critically important to continuing to discover novel treatments for patients suffering from a variety of diseases," said Brian Kotzin, MD, vice president of Global Development at Amgen. "These data give us insight into the importance of TSLP as a mediator of asthmatic response and the ability to inhibit inflammation in asthma."
MEDI9929/AMG 157[1] is being jointly developed by Amgen and AstraZeneca, with its global biologics research and development arm MedImmune. MEDI9929/AMG 157 is currently in Phase II development for the treatment of asthma.
"We are encouraged by these early results and look forward to leading further development of this promising new biologic in partnership with Amgen," said Bing Yao, PhD, senior vice president and head of MedImmune's Respiratory, Inflammation and Autoimmunity Innovative Medicines Unit. "The goal of the Phase II study is to understand if this approach could provide benefit for patients with severe asthma."
Reference
[1] As part of the collaboration agreement, the compound reference number has been changed from AMG 157 to MEDI9929/AMG 157. Phase II clinical studies are referenced on clinicaltrials.gov under MEDI9929 or AMG 157.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance